Axsome Therapeutics - AXSM Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $119.67
Forecasted Upside: 67.98%
Number of Analysts: 12
Breakdown:
0 Sell Ratings
1 Hold Ratings
11 Buy Ratings
0 Strong Buy Ratings

^$71.24 As of 04/25/2024 02:07 PM ET

▲ +0.07 (0.10%)

1 month | 3 months | 12 months

Get New Axsome Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AXSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXSM

^$119.67

▲ +67.98% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $119.67, with a high forecast of $190.00 and a low forecast of $81.00. The average price target represents a 67.98% upside from the last price of $71.24.

Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Axsome Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/2/2022

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/31/2023

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/1/2023

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/30/2023

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/26/2024

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/26/2024

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$107.00	Low
4/2/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$190.00	Low
3/28/2024	Mizuho	Boost Target	Buy ➝ Buy	$108.00 ➝ $109.00	N/A
3/26/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$150.00	Low
3/26/2024	HC Wainwright	Boost Target	Buy ➝ Buy	$180.00 ➝ $190.00	Low
3/26/2024	Citigroup	Boost Target	Buy ➝ Buy	$125.00 ➝ $127.00	Low
3/26/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$123.00 ➝ $128.00	Low
3/20/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$180.00	Low
3/19/2024	Robert W. Baird	Initiated Coverage	Outperform	$108.00	Low
3/4/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$180.00	Low
2/27/2024	Mizuho	Lower Target	Buy ➝ Buy	$112.00 ➝ $108.00	Low
2/21/2024	Guggenheim	Boost Target	Buy ➝ Buy	$110.00 ➝ $125.00	Low
2/21/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$126.00 ➝ $123.00	Low
2/20/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$108.00	Low
2/16/2024	Mizuho	Boost Target	Buy ➝ Buy	$90.00 ➝ $112.00	Low
2/6/2024	UBS Group	Initiated Coverage	Buy	$111.00	Low
1/25/2024	Royal Bank of Canada	Initiated Coverage	Outperform	$126.00	Low
1/22/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$108.00	Low
1/16/2024	Piper Sandler	Boost Target	Overweight ➝ Overweight	$90.00 ➝ $113.00	Low
12/26/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$180.00	Low
12/20/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$108.00	Low
12/13/2023	Citigroup	Initiated Coverage	Buy	$125.00	Low
12/12/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$180.00	Low
11/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$108.00	Low
9/25/2023	Mizuho	Reiterated Rating	Buy ➝ Buy	$100.00	Low
8/28/2023	Mizuho	Reiterated Rating	Buy ➝ Buy	$100.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$108.00	Low
8/11/2023	Mizuho	Boost Target	Buy ➝ Buy	$95.00 ➝ $100.00	Low
8/8/2023	HC Wainwright	Lower Target	Buy ➝ Buy	$190.00 ➝ $180.00	Low
8/8/2023	Bank of America	Upgrade	Underperform ➝ Neutral	$59.00 ➝ $81.00	Low
8/7/2023	Piper Sandler	Upgrade	Neutral ➝ Overweight	$70.00 ➝ $90.00	Low
8/7/2023	William Blair	Reiterated Rating	Outperform		Low
7/17/2023	HC Wainwright	Lower Target		$200.00 ➝ $190.00	Low
6/22/2023	VNET Group	Reiterated Rating	Reiterates		Low
5/11/2023	Mizuho	Boost Target		$84.00 ➝ $95.00	Low
5/9/2023	Guggenheim	Boost Target		$90.00 ➝ $100.00	Low
5/9/2023	Morgan Stanley	Boost Target		$83.00 ➝ $87.00	Low
4/17/2023	HC Wainwright	Reiterated Rating	Buy	$200.00	Low
4/12/2023	Morgan Stanley	Lower Target	Equal Weight	$85.00 ➝ $83.00	Low
3/20/2023	HC Wainwright	Lower Target		$210.00 ➝ $200.00	Low
3/13/2023	Mizuho	Reiterated Rating	Buy	$84.00	Low
3/6/2023	HC Wainwright	Reiterated Rating	Buy	$210.00	Low
3/1/2023	Mizuho	Lower Target	Buy	$86.00 ➝ $84.00	Low
2/28/2023	Guggenheim	Lower Target	Buy	$105.00 ➝ $90.00	Low
2/28/2023	Morgan Stanley	Lower Target	Equal Weight	$86.00 ➝ $85.00	Low
2/14/2023	Bank of America	Reiterated Rating	Underperform	$52.00	Low
2/14/2023	HC Wainwright	Reiterated Rating	Buy	$210.00	N/A
1/30/2023	Mizuho	Boost Target	Buy	$80.00 ➝ $86.00	Low
1/5/2023	Piper Sandler	Initiated Coverage	Neutral	$75.00	Low
12/23/2022	BTIG Research	Boost Target	Buy	$62.00 ➝ $98.00	Low
11/29/2022	Morgan Stanley	Boost Target	Equal Weight	$73.00 ➝ $86.00	Low
11/29/2022	SVB Leerink	Boost Target	Outperform	$65.00 ➝ $85.00	Low
11/28/2022	Mizuho	Reiterated Rating	Buy	$80.00	Low
11/15/2022	Mizuho	Boost Target		$80.00	N/A
11/11/2022	Guggenheim	Boost Target	Buy	$72.00 ➝ $80.00	Low
11/9/2022	Mizuho	Boost Target	Buy	$76.00 ➝ $80.00	Low
11/8/2022	Morgan Stanley	Lower Target	Equal Weight	$74.00 ➝ $73.00	Low
11/8/2022	Cantor Fitzgerald	Boost Target		$88.00 ➝ $96.00	Low
11/1/2022	Loop Capital	Initiated Coverage	Buy	$95.00	Low
10/14/2022	Morgan Stanley	Boost Target	Equal Weight	$71.00 ➝ $74.00	Low
10/14/2022	Guggenheim	Boost Target	Buy	$64.00 ➝ $72.00	Low
10/5/2022	Cowen	Lower Target		$125.00	Low
10/4/2022	HC Wainwright	Reiterated Rating	Buy	$210.00	Low
9/30/2022	Morgan Stanley	Lower Target	Equal Weight	$75.00 ➝ $71.00	Low
9/30/2022	Jefferies Financial Group	Lower Target	Buy	$92.00 ➝ $90.00	Low
9/7/2022	Mizuho	Boost Target	Buy	$49.00 ➝ $76.00	Low
8/30/2022	Morgan Stanley	Boost Target	Equal Weight	$55.00 ➝ $75.00	Low
8/23/2022	HC Wainwright	Boost Target	Buy	$180.00 ➝ $210.00	Low
8/22/2022	SVB Leerink	Boost Target		$50.00 ➝ $75.00	Low
8/19/2022	Truist Financial	Boost Target		$100.00 ➝ $150.00	Low
8/10/2022	Cantor Fitzgerald	Lower Target		$64.00 ➝ $54.00	Low
8/10/2022	Morgan Stanley	Boost Target	Equal Weight	$54.00 ➝ $55.00	Low
7/8/2022	Morgan Stanley	Boost Target	Equal Weight	$27.00 ➝ $54.00	N/A
6/29/2022	Cowen	Boost Target	Outperform	$120.00 ➝ $130.00	Low
6/29/2022	Cowen	Boost Target	Outperform	$120.00 ➝ $130.00	Low
6/29/2022	Cantor Fitzgerald	Boost Target	Overweight	$47.00 ➝ $64.00	Low
5/3/2022	Mizuho	Lower Target		$51.00 ➝ $49.00	High
3/29/2022	Jefferies Financial Group	Boost Target	Buy	$71.00 ➝ $77.00	High
3/2/2022	SVB Leerink	Lower Target	Outperform	$65.00 ➝ $50.00	Low
11/18/2021	Mizuho	Lower Target	Buy	$55.00 ➝ $51.00	High
11/9/2021	Cantor Fitzgerald	Reiterated Rating	Overweight		High
11/9/2021	SVB Leerink	Lower Target	Outperform	$75.00 ➝ $65.00	High
9/15/2021	HC Wainwright	Reiterated Rating	Buy	$180.00	Low
8/30/2021	HC Wainwright	Reiterated Rating	Buy	$225.00 ➝ $180.00	Low
8/27/2021	William Blair	Reiterated Rating	Buy		Low
8/23/2021	Mizuho	Reiterated Rating	Buy	$55.00	High
8/10/2021	BTIG Research	Lower Target	Buy ➝ Buy	$123.00 ➝ $55.00	High
8/10/2021	SVB Leerink	Lower Target	Positive ➝ Outperform	$115.00 ➝ $75.00	High
8/10/2021	Truist Financial	Lower Target	Buy	$200.00 ➝ $160.00	High
8/10/2021	Mizuho	Lower Target	Buy	$118.00 ➝ $55.00	High
8/10/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$105.00 ➝ $34.00	High
7/16/2021	William Blair	Set Target	Buy	$56.77	High
6/10/2021	Berenberg Bank	Initiated Coverage	Buy	$112.00	High
5/26/2021	Morgan Stanley	Boost Target	Overweight	$104.00 ➝ $105.00	Medium
5/12/2021	BTIG Research	Reiterated Rating	Buy		Low
4/27/2021	HC Wainwright	Boost Target	Buy	$210.00 ➝ $225.00	High
3/2/2021	Mizuho	Lower Target	Buy	$120.00 ➝ $118.00	Low
3/2/2021	Morgan Stanley	Boost Target	Overweight	$101.00 ➝ $104.00	Low
1/8/2021	Jefferies Financial Group	Initiated Coverage	Buy	$129.00	Low
12/31/2020	UBS Group	Reiterated Rating	Positive		N/A
12/15/2020	Mizuho	Initiated Coverage	Buy	$120.00	Low
12/3/2020	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$131.00 ➝ $161.00	High
11/9/2020	Morgan Stanley	Lower Target	Overweight	$102.00 ➝ $101.00	Low
10/1/2020	William Blair	Reiterated Rating	Buy		Low
9/29/2020	Bank of America	Initiated Coverage	Underperform	$66.00	High
9/10/2020	Morgan Stanley	Initiated Coverage	Overweight	$102.00	Low
9/4/2020	William Blair	Reiterated Rating	Buy		N/A
8/21/2020	William Blair	Reiterated Rating	Buy		Low
8/10/2020	William Blair	Reiterated Rating	Buy		Medium
8/6/2020	HC Wainwright	Reiterated Rating	Buy	$210.00	Low
7/14/2020	HC Wainwright	Reiterated Rating	Buy	$210.00	Medium
6/30/2020	HC Wainwright	Reiterated Rating	Buy	$210.00	High
4/28/2020	Guggenheim	Boost Target	In-Line ➝ Buy	$158.00 ➝ $200.00	Medium
4/28/2020	HC Wainwright	Boost Target	Buy	$200.00 ➝ $210.00	Medium
4/27/2020	Cantor Fitzgerald	Boost Target	Overweight	$125.00 ➝ $131.00	Low
4/27/2020	LADENBURG THALM/SH SH	Boost Target	Positive ➝ Buy	$165.00 ➝ $186.00	Low
4/27/2020	SunTrust Banks	Boost Target	Positive ➝ Buy	$145.00 ➝ $200.00	High
4/14/2020	Cowen	Initiated Coverage	Outperform	$95.00	High
4/6/2020	William Blair	Reiterated Rating	Buy		High
4/6/2020	HC Wainwright	Reiterated Rating	Buy	$200.00	High
3/16/2020	HC Wainwright	Reiterated Rating	Buy	$200.00	High
2/24/2020	HC Wainwright	Reiterated Rating	Buy	$200.00	Low
1/28/2020	HC Wainwright	Reiterated Rating	Buy	$200.00	High
1/21/2020	HC Wainwright	Reiterated Rating	Buy		Medium
1/14/2020	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$139.00 ➝ $165.00	Medium
1/2/2020	SunTrust Banks	Boost Target	Buy	$140.00	Medium
12/30/2019	BTIG Research	Boost Target	Buy	$97.00	Medium
12/30/2019	LADENBURG THALM/SH SH	Boost Target	Buy	$139.00 ➝ $165.00	Low
12/30/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$104.00 ➝ $125.00	Medium
12/24/2019	HC Wainwright	Reiterated Rating	Buy	$170.00 ➝ $200.00	Medium
12/17/2019	SunTrust Banks	Boost Target	Buy	$100.00	High
12/17/2019	BTIG Research	Boost Target	Buy ➝ Positive	$97.00	High
12/16/2019	Piper Sandler Companies	Reiterated Rating	Buy	$125.00	Medium
12/16/2019	Cantor Fitzgerald	Boost Target	Overweight	$55.00 ➝ $104.00	High
12/4/2019	Guggenheim	Boost Target		$65.00 ➝ $48.00	High
12/4/2019	SunTrust Banks	Reiterated Rating	Buy ➝ Positive	$60.00	High
12/4/2019	BTIG Research	Reiterated Rating	Buy ➝ Positive	$48.00	Medium
12/3/2019	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$45.00 ➝ $55.00	High
11/26/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$45.00	High
10/17/2019	HC Wainwright	Reiterated Rating	Buy	$30.00	High
10/16/2019	Guggenheim	Initiated Coverage	Buy	$48.00	High
9/18/2019	William Blair	Initiated Coverage	Outperform	$48.00	Low
6/24/2019	HC Wainwright	Set Target	Buy	$30.00	Low
5/28/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$25.00 ➝ $35.00	Low
5/28/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy		Low
5/23/2019	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $30.00	High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

7 very positive mentions
4 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

9/28/2023

3 very positive mentions
5 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

10/28/2023

2 very positive mentions
8 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

11/27/2023

6 very positive mentions
17 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

12/27/2023

5 very positive mentions
20 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

1/26/2024

18 very positive mentions
19 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

2/25/2024

17 very positive mentions
23 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

3/26/2024

12 very positive mentions
11 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Today's Range

Now: $71.24

$69.53

$72.38

50 Day Range

MA: $76.15

$65.72

$93.46

52 Week Range

Now: $71.24

$55.02

$98.40

Volume

163,007 shs

Average Volume

720,349 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Axsome Therapeutics?: The following Wall Street analysts have issued reports on Axsome Therapeutics in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, Truist Financial Co., UBS Group AG, VNET Group, Inc., and William Blair.
View the latest analyst ratings for AXSM.
What is the current price target for Axsome Therapeutics?: 12 Wall Street analysts have set twelve-month price targets for Axsome Therapeutics in the last year. Their average twelve-month price target is $119.67, suggesting a possible upside of 68.0%. HC Wainwright has the highest price target set, predicting AXSM will reach $190.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $81.00 for Axsome Therapeutics in the next year.
View the latest price targets for AXSM.
What is the current consensus analyst rating for Axsome Therapeutics?: Axsome Therapeutics currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AXSM.
What other companies compete with Axsome Therapeutics?: Other companies that are similar to Axsome Therapeutics include Prestige Consumer Healthcare, Insmed, Biohaven, Ultragenyx Pharmaceutical and CymaBay Therapeutics. Learn More about companies similar to Axsome Therapeutics.
How do I contact Axsome Therapeutics' investor relations team?: Axsome Therapeutics' physical mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company's listed phone number is (212) 332-3241. The official website for Axsome Therapeutics is axsome.com. Learn More about contacing Axsome Therapeutics investor relations.

Axsome Therapeutics - AXSM Stock Price Target and Predictions

Analyst Price Target for AXSM

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.72 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Axsome Therapeutics?

What is the current price target for Axsome Therapeutics?

What is the current consensus analyst rating for Axsome Therapeutics?

What other companies compete with Axsome Therapeutics?

How do I contact Axsome Therapeutics' investor relations team?